Memantine works by reducing excessive glutamate-driven activity at NMDA receptors, which help brain cells communicate. In moderate-to-severe Alzheimer's disease, this can produce small benefits in thinking, daily function, and behavior, but it does not cure the disease or stop neurodegeneration. In the United States, the FDA prescribing information approves memantine for moderate-to-severe dementia of the Alzheimer's type. It is not approved as a general treatment for every disease that causes dementia.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does memantine do in the brain?
- How much benefit can families expect?
- Who is memantine intended for?
- Can memantine be combined with donepezil?
- What should caregivers monitor?
What does memantine do in the brain?
Glutamate is involved in normal brain-cell signaling. When glutamate keeps NMDA receptor channels excessively active, however, that persistent stimulation may disrupt communication between cells. memantine is a low-to-moderate-affinity, uncompetitive open-channel blocker.
In practical terms, it acts when an NMDA channel is open and reduces excessive activity without completely shutting down the brief signaling needed for normal communication, according to DailyMed's prescribing information. This mechanism explains why memantine may ease symptoms without changing the underlying course of Alzheimer's. The official label states that there is no evidence it prevents or slows Alzheimer-related neurodegeneration.
How much benefit can families expect?
A 2019 Cochrane review examined up to 14 trials involving about 3,700 people with moderate-to-severe Alzheimer's disease. It found high-certainty evidence of small benefits in cognition, daily activities, and behavior or mood compared with placebo. "Small benefit" is an important qualifier.
Treatment may mean somewhat less deterioration rather than a return to earlier abilities, and an average trial result cannot predict one person's response. Disease stage also matters. In mild Alzheimer's disease, available evidence found memantine was probably no better than placebo for cognition, daily function, or behavior.
Who is memantine intended for?
The clearest case is someone with diagnosed Alzheimer's dementia that has reached the moderate or severe stage. A practical discussion with the prescriber should establish: Evidence for vascular, Lewy-body, Parkinson's, and frontotemporal dementias is limited or less certain. A person's diagnosis should therefore be confirmed rather than treating "dementia" as a single condition with one medication plan.
- Whether Alzheimer's disease is the identified cause of dementia
- Whether the condition is moderate or severe
- Whether the person already takes donepezil or another cholinesterase inhibitor
- Whether severe kidney impairment requires a lower target dose
- Which changes in cognition, daily activities, or behavior will be monitored
Can memantine be combined with donepezil?
Memantine can be used alongside a cholinesterase inhibitor such as donepezil. Trials and NICE guidance indicate that combination treatment can produce less deterioration in moderate or severe Alzheimer's disease.
Combination treatment is not automatically the right choice for everyone. If someone already takes donepezil, the useful question is whether adding memantine fits that person's diagnosis, disease stage, kidney function, and treatment goals.
What should caregivers monitor?
Prescribers usually increase memantine gradually rather than beginning at the full target dose. The target dose is reduced in severe renal impairment because the kidneys help clear the medication.
Common adverse effects include dizziness, headache, confusion, and constipation, as described by MedlinePlus. Caregivers can record when a symptom began, how it affects daily activities, and whether it appeared after a dose increase, then share those details with the prescriber.
